Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapi...
Aspect Biosystems has expanded its partnership with Novo Nordisk to develop bioprinted islet therapies for Type 1 diabetes. Building on a 2.6 billion dollar framework, this new phase adds equity inves...